Your institution may have access to this item. Find your institution then sign in to continue.
Title
Edison Liu.
Abstract
An interview with Genome Institute of Singapore executive director Edison Liu is presented. When asked about the changes in the drug and diagnostic markets in Asia, he mentions the combined effects of the dominant size of the Chinese and Indian markets and the importance of their views on health financing. Liu believes that medical information technology (IT) will be a major sector in the biomedical economy, wherein Asian firms can gain significant market share. He discusses the impact of the changing global landscape on biotechnology and drug firms.